Children's Mercy Kansas City

SHARE @ Children's Mercy
Manuscripts, Articles, Book Chapters and Other Papers
10-1-2014

Impact of pre-stage II hemodynamics and pulmonary artery
anatomy on 12-month outcomes in the Pediatric Heart Network
Single Ventricle Reconstruction trial.
Ranjit Aiyagari
John F. Rhodes
Peter Shrader
Wolfgang A. Radtke
Varsha M. Bandisode

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers
Part of the Cardiology Commons, Cardiovascular Diseases Commons, Congenital, Hereditary, and
Neonatal Diseases and Abnormalities Commons, Pediatrics Commons, and the Surgery Commons

Recommended Citation
Aiyagari, R., Rhodes, J. F., Shrader, P., Radtke, W. A., Bandisode, V. M., Bergersen, L., Gillespie, M. J., Gray, R.
G., Guey, L. T., Hill, K. D., Hirsch, R., Kim, D. W., Lee, K., Pelech, A. N., Ringewald, J., Takao, C., Vincent, J. A.,
Ohye, R. G., ., Shirali, G. S. Impact of pre-stage II hemodynamics and pulmonary artery anatomy on
12-month outcomes in the Pediatric Heart Network Single Ventricle Reconstruction trial. The Journal of
thoracic and cardiovascular surgery 148, 1467-1474 (2014).

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for
inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @
Children's Mercy. For more information, please contact library@cmh.edu.

Creator(s)
Ranjit Aiyagari, John F. Rhodes, Peter Shrader, Wolfgang A. Radtke, Varsha M. Bandisode, Lisa Bergersen,
Matthew J. Gillespie, Robert G. Gray, Lin T. Guey, Kevin D. Hill, Russel Hirsch, Dennis W. Kim, Kyong-Jin
Lee, Andrew N. Pelech, Jeremy Ringewald, Cheryl Takao, Julie A. Vincent, Richard G. Ohye, Pediatric Heart
Network Investigators, and Girish S. Shirali

This article is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/papers/404

Aiyagari et al

Congenital Heart Disease

Impact of pre–stage II hemodynamics and pulmonary artery
anatomy on 12-month outcomes in the Pediatric Heart Network
Single Ventricle Reconstruction trial
Ranjit Aiyagari, MD,a John F. Rhodes, MD,b Peter Shrader, MA,c Wolfgang A. Radtke, MD,d
Varsha M. Bandisode, MD,e Lisa Bergersen, MD,f Matthew J. Gillespie, MD,g Robert G. Gray, MD,h
Lin T. Guey, PhD,c Kevin D. Hill, MD,b Russel Hirsch, MD,i Dennis W. Kim, MD, PhD,j
Kyong-Jin Lee, MD,k Andrew N. Pelech, MD,l Jeremy Ringewald, MD,m Cheryl Takao, MD,n
Julie A. Vincent, MD,o and Richard G. Ohye, MD,p for the Pediatric Heart Network Investigators
Objective: To compare the interstage cardiac catheterization hemodynamic and angiographic findings between
shunt types for the Pediatric Heart Network Single Ventricle Reconstruction trial. The trial, which randomized
subjects to a modified Blalock-Taussig shunt (MBTS) or right ventricle-to-pulmonary artery shunt (RVPAS) for
the Norwood procedure, demonstrated the RVPAS was associated with a smaller pulmonary artery diameter but
superior 12-month transplant-free survival.
Methods: We analyzed the pre–stage II catheterization data for the trial subjects. The hemodynamic variables
and shunt and pulmonary angiographic data were compared between shunt types; their association with
12-month transplant-free survival was also evaluated.
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Results: Of 549 randomized subjects, 389 underwent pre–stage II catheterization. A smaller size, lower aortic
and superior vena cava saturation, and higher ventricular end-diastolic pressure were associated with worse 12month transplant-free survival. The MBTS group had a lower coronary perfusion pressure (27 vs 32 mm Hg;
P<.001) and greater pulmonary blood flow/systemic blood flow ratio (1.1 vs 1.0, P ¼ .009). A greater pulmonary blood flow/systemic blood flow ratio increased the risk of death or transplantation only in the RVPAS group
(P ¼ .01). The MBTS group had fewer shunt (14% vs 28%, P ¼ .004) and severe left pulmonary artery (0.7% vs
9.2%, P ¼ .003) stenoses, larger mid-main branch pulmonary artery diameters, and greater Nakata indexes
(164 vs 134, P <.001).
Conclusions: Compared with the RVPAS subjects, the MBTS subjects had more hemodynamic abnormalities
related to shunt physiology, and the RVPAS subjects had more shunt or pulmonary obstruction of a severe degree
and inferior pulmonary artery growth at pre–stage II catheterization. A lower body surface area, greater ventricular end-diastolic pressure, and lower superior vena cava saturation were associated with worse 12-month
transplant-free survival. (J Thorac Cardiovasc Surg 2014;148:1467-74)
Despite significant advances in staged surgical repair
for infants with single ventricle anatomy, the early- and
intermediate-term outcomes have remained suboptimal.1,2
The palliative approach for these infants has consisted of
a Norwood procedure using either a modified BlalockTaussig shunt (MBTS) or right ventricle-to-pulmonary

artery shunt (RVPAS) to supply blood flow to the lungs.
Then, usually at 3 to 7 months of age, a stage II procedure
will be performed, most often after elective pre–stage II
cardiac catheterization with angiography of the shunt
and pulmonary arteries. Few data exist regarding the
importance of the pre–stage II assessment using cardiac

From the Division of Pediatric Cardiology,a University of Michigan Medical School,
Ann Arbor, Mich; Duke University Medical Center,b Durham, NC; New England
Research Institute,c Watertown, Mass; Nemours Cardiac Center,d Wilmington,
Del; Department of Pediatrics,e Medical University of South Carolina, Charleston,
SC; Department of Cardiology,f Children’s Hospital Boston, Boston, Mass; Division of Pediatric Cardiology,g Children’s Hospital of Philadelphia, Philadelphia,
Pa; Division of Pediatric Cardiology,h University of Utah, Salt Lake City, Utah;
Cincinnati Children’s Hospital Medical Center,i Cincinnati, Ohio; Children’s
Healthcare of Atlanta,j Emory University, Atlanta, Ga; The Hospital for Sick
Children,k Toronto, Ontario, Canada; Department of Pediatrics,l Medical College
of Wisconsin, Milwaukee, Wis; Division of Cardiology,m All Children’s Hospital,
St Petersburg, Fla; Division of Pediatric Cardiology,n Children’s Hospital
Los Angeles, Los Angeles, Calif; Division of Cardiology,o New York-Presbyterian
Morgan Stanley Children’s Hospital, New York, NY; and Section of Pediatric

Cardiovascular Surgery,p University of Michigan Medical School, Ann Arbor,
Mich.
This study was supported by U01 grants from the National Heart, Lung, and Blood
Institute (grants HL068269, HL068270, HL068279, HL068281, HL068285,
HL068292, HL068290, HL068288, HL085057, HL109781, and HL109737).
Disclosures: Authors have nothing to disclose with regard to commercial support.
Received for publication July 24, 2013; revisions received Oct 18, 2013; accepted for
publication Oct 27, 2013; available ahead of print Dec 13, 2013.
Address for reprints: Ranjit Aiyagari, MD, Division of Pediatric Cardiology,
University of Michigan Medical School, 1540 E Hospital Drive, Ann Arbor,
MI 48109-4204 (E-mail: ranjita@umich.edu).
0022-5223/$36.00
Copyright Ó 2014 by The American Association for Thoracic Surgery
http://dx.doi.org/10.1016/j.jtcvs.2013.10.057

The Journal of Thoracic and Cardiovascular Surgery c Volume 148, Number 4
Downloaded for Anonymous User (n/a) at The Children's Mercy Hospital - Kansas City from ClinicalKey.com by Elsevier on October 15, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.

1467

Congenital Heart Disease

Abbreviations and Acronyms
BSA ¼ body surface area
CI
¼ confidence interval
EDP ¼ end-diastolic pressure
HR
¼ hazard ratio
LPA
¼ left pulmonary artery
MBTS ¼ modified Blalock-Taussig shunt
Qp/Qs ¼ pulmonary blood flow/systemic blood
flow
RPA ¼ right pulmonary artery
RVPAS ¼ right ventricle-to-pulmonary artery shunt
SVC ¼ superior vena cava
SVR ¼ single ventricle reconstruction
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absence) and obstructed pulmonary venous return (presence vs absence),
with dynamic allocation by the surgeon. Details regarding the trial design
have been previously published.9 The institutional review board at all
participating institutions approved the trial (ClinicalTrials.gov no.
NCT00115934), and the parents or guardians provided informed consent
for each subject.
All subjects enrolled in the SVR trial who had undergone pre–stage II
cardiac catheterization were included in these analyses. Infants who had
died before undergoing the stage II procedure but who had undergone cardiac catheterization and had acceptable angiograms were also included in
the analyses. The only subjects excluded were those who had not undergone cardiac catheterization with angiography of the shunt and pulmonary
arteries before the stage II procedure or those who survived but had never
undergone stage II palliation. The subjects for whom the angiograms were
deemed inadequate by the Angiography Core Laboratory were included for
the hemodynamic analyses.

Catheterization Hemodynamic Variables
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catheterization and the importance of these findings to the
outcomes.3,4
Recently, several nonrandomized studies have reported
improved early outcomes after Norwood procedures
using a RVPAS.5-7 The Pediatric Heart Network Single
Ventricle Reconstruction (SVR) trial was a multiinstitutional trial that evaluated the early- and intermediateterm outcomes for infants undergoing a Norwood procedure
randomized to either an MBTS or RVPAS. The initial SVR
trial results8 demonstrated that the RVPAS, compared
with the MBTS, was associated with superior 12-month
transplant-free survival. However, at>12 months, no significant transplant-free survival difference was found between
the 2 groups. However, that primary SVR analysis also
demonstrated that the RVPAS subjects had undergone
significantly more unintended cardiovascular procedures.
In addition, analysis of the pre–stage II angiograms for pulmonary artery growth, a secondary endpoint of the SVR
trial, demonstrated worse branch pulmonary artery growth
before the stage II procedure for the RVPAS group
compared with the MBTS group.8 However, the level of
detail of the angiographic analysis was limited. The hemodynamic measures were not analyzed in the initial SVR
publication.
The purposes of the present analysis were to describe in
detail the cardiovascular hemodynamics and shunt or
branch pulmonary artery angiographic findings from the
pre–stage II cardiac catheterization; to assess the differences in these measures stratified by the shunt type; and
to evaluate the effect of these factors on 12-month
transplant-free survival.
METHODS
Study Population and Design
From May 2005 to July 2008, 15 North American centers randomized
549 infants with single ventricle anatomy in the SVR trial to MBTS or
RVPAS. Randomization was stratified by aortic atresia (presence vs
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The hemodynamic variables were collected prospectively for each
enrolled subject. These data were collected during catheterization at a baseline state, defined as the period when the subject was stable and before any
intervention. The type of sedation and presence or absence of supplemental
oxygen were recorded. If>1 measurement was obtained, the average of all
stable baseline measurements was recorded. The coronary perfusion pressure was calculated as the aortic or femoral artery diastolic pressure minus
the ventricular end-diastolic pressure (EDP).

Shunt and Pulmonary Angiographic Measurements
The Angiography Core Laboratory received the angiograms, which
were blinded for the subjects’ demographic data and medical center location. All angiograms were assessed for the presence of a reliable calibration factor, and the image quality was scored to determine whether the
angiograms were acceptable to perform complete measurements. Each
measurement was performed to the nearest 0.1 mm either digitally
(Philips Inturis, Digital Angiographic Analysis, Eindhoven, The
Netherlands) or using digital calipers (Absolute, Digimatic, Mitutoya,
Japan). The measurements were conducted separately by 2 physicians
trained in angiography. If a significant discrepancy was present, the study
was reviewed again and adjudicated such that discrepancies were
resolved before entering the final data from the Angiography Core Laboratory. For the right and left pulmonary arteries (RPA and LPA, respectively), specific measurement locations (Figure 1) were defined as the
mid-main branch pulmonary artery (between the shunt anastomosis
and upper lobe branch or proximal to the upper lobe branch for the
side contralateral to the shunt) and the proximal lower lobe branch pulmonary artery (between the takeoff of the upper lobe branch and the
lower lobe segments). These specific locations were selected to avoid
measuring stenotic areas as representative of pulmonary artery growth
in the often-complex anatomy. The Nakata index was measured using
the following formula: p 3 [right mid-main pulmonary artery diameter
(mm)2 þ left mid-main pulmonary artery diameter (mm)2]/[4 3 body
surface area (m2)].10 In addition, the angiograms were assessed for the
presence of shunt stenosis (proximal or distal) and unilateral and bilateral
branch pulmonary artery stenosis. The percentage of stenosis was calculated using the following formula: [1  (diameter of narrowest portion of
the stenotic branch pulmonary artery/diameter of ipsilateral proximal
lower lobe branch)] 3 100. The severity of branch pulmonary artery stenosis was quantified as none (<15%), mild (15%-35%), moderate
(>35%-50%), or severe (>50%).

Statistical Analysis
Shunt comparisons were performed using the Student t test or Wilcoxon
rank sum test, as appropriate, for continuous measures. Categorical
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FIGURE 1. Location of branch pulmonary artery measurements. Diamonds mark the mid-main pulmonary artery measurement location, and circles mark
the proximal lower lobe pulmonary artery measurement location. MBTS, Modified Blalock-Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt.

RESULTS
Study Population
Of the 549 SVR trial subjects, the present analysis was
restricted to the 389 subjects who had undergone prestage
II cardiac catheterization, including 348 subjects with
angiograms deemed adequate for analysis (MBTS,
n ¼ 152; RVPAS, n ¼ 196; Figure 2). The reasons that
catheterization was not performed are summarized in
Figure 2 and included in-hospital death or transplant
(n ¼ 97), interstage death or transplantation (n ¼ 45), and
institutional preference (n ¼ 18). Age, body surface area
(BSA), and angiogram acceptability did not differ between
shunt types (Table 1). The BSA at initial palliation also did
not differ by shunt type (P ¼ .63), and the frequency of a
low BSA did not differ between the 2 groups at either the
initial surgical palliation (P ¼ .30) or catheterization
(P ¼ .84). Of those with adequate pre–stage II cardiac
catheterization angiograms, 23 subjects (6.6%) had either
died or underwent cardiac transplantation after the stage

II procedure and before the 12-month point after randomization (MBTS, 6%; RVPAS, 7%).
Sedation Type
For the entire cohort undergoing cardiac catheterization,
the procedure was performed with the patient under general
anesthesia for 63% of the patients and using intravenous
sedation for the remaining 37%. The RVPAS patients
were more likely to be placed under general anesthesia
were the MBTS patients (69% vs 56%, P ¼ .01).
Cardiovascular Hemodynamic Variables
For the entire cohort, 3 anthropometric or hemodynamic
variables obtained at pre–stage II cardiac catheterization
demonstrated associations on univariate analysis with transplantation or death at 12 months. These included the BSA
(HR per standard deviation decrease, 1.87; 95% CI, 1.322.64; P < .001), superior vena caval saturation (HR per
1% decrease, 1.07; 95% CI, 1.03-1.12; P ¼ .002), and ventricular EDP (HR per 1-mm Hg increase, 1.17; 95% CI,
1.07-1.30; P ¼ .006). A larger pulmonary blood flow/systemic blood flow (Qp/Qs) ratio was associated with an
increased risk only for the RVPAS group (HR per 0.1 increase, 1.11; 95% CI, 1.02-1.21; P ¼ .01).
The hemodynamic data examined by shunt type (Table 2)
demonstrated that the MBTS group, compared with the
RVPAS group, had a greater Qp/Qs ratio, a significantly
lower systemic diastolic pressure, and calculated coronary
perfusion pressure but a similar systemic ventricle EDP.
Shunt and Pulmonary Artery Abnormalities
Overall, 55% of subjects had angiographic findings of
shunt or branch pulmonary artery stenosis, including 33%
with moderate or worse (>35%) branch pulmonary artery
stenosis (Table 3). The RVPAS group demonstrated more
frequent shunt stenosis (MBTS 14% vs RVPAS 28%;
P ¼ .004). When the location of shunt stenosis was
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measures were compared by shunt type using the Fisher exact test. Ordinal
measures were also compared using the Mantel-Haenszel’s test for trend.
The shunt type used in statistical analyses was the actual shunt type in
place at the end of the Norwood procedure and, thus, represented a
non–intention-to-treat analysis. Hazard ratios (HRs) and the associations
between the hemodynamic variables and angiographic measurements
and 12-month transplant-free survival were examined using the Cox
proportional hazards model. Interactions between the shunt type and the
hemodynamic and angiographic measures were examined. Continuous
measures were examined as quartiles when nonlinear associations were
identified. Owing to the limited number of deaths and transplantations in
the subjects with cardiac catheterization data, multivariate analysis was
not practical; therefore, the associations with 12-month transplant-free
survival were unadjusted. The proportional hazards assumption was
examined for each measure. The incidence rates and 95% confidence
intervals (CIs) for catheter interventions were calculated using Poisson’s
regression. The presented P values are raw and were not adjusted for
multiple comparisons. Owing to the large number of comparisons
performed, P  .01 was considered statistically significant. All analyses
were performed using the Statistical Analysis Systems, version 9.2
(SAS Institute, Inc, Cary, NC) and R, version 2.12.0 (University of Auckland, Auckland, New Zealand).
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FIGURE 2. Single Ventricle Reconstruction trial subjects’ outcomes and subgroup with acceptable prestage II angiograms. MBTS, Modified BlalockTaussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt.

assessed, the RVPAS group had developed proximal shunt
stenosis more often, and the distal shunt stenosis rates
were similar between the 2 groups. The total pulmonary
artery growth was also decreased in the RVPAS group, as
reflected by the smaller right and left mid-main branch
pulmonary artery diameters and the smaller proximal right
lower lobe and lower Nakata index (Table 4). For the entire
cohort, severe (>50%) branch pulmonary artery stenosis
occurred in 9.5% in the RPA and 5.5% in the LPA. The
rate of severe RPA stenosis did not differ between the 2
groups (MBTS 5.9% vs RVPAS 12%, P ¼ .18). However,
the MBTS subjects less often developed severe LPA
TABLE 1. Demographic data by shunt type
Variable

Total

MBTS

RVPAS

Cardiac catheterization
Acceptable angiograms for
analysis
Age at catheterization (mo)
Body surface area (m2)

389
348

170
152

217
196

4.4  1.5
0.31  0.04

4.5  1.5
0.31  0.04

4.4  1.5
0.31  0.04

Data presented as n or mean  standard deviation. MBTS, Modified Blalock-Taussig
shunt; RVPAS, right ventricle-to-pulmonary artery shunt.
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stenosis (MBTS 0.7% vs RVPAS 9.2%, P ¼ .003). When
comparing the narrowest diameter of the stenotic branch
pulmonary artery segment, the RVPAS group had a smaller
diameter for the stenotic portion of the RPA (2.9  0.9 mm
vs 4.0  1.3 mm, P<.001) but not the LPA (2.9  1.0 mm
vs 3.3  1.0 mm, P ¼ .06).
For the entire cohort, no single angiographic measurement was associated with the 12-month transplant-free
survival. The Nakata index also was not predictive of the
12-month transplant-free survival.
DISCUSSION
Our analysis represents the first prospective study to
examine in detail the hemodynamic and angiographic variables and their relationship with the outcome in patients
after Norwood procedure randomized to the MBTS or
RVPAS.
Hemodynamic Parameters
The hemodynamic measures associated with an increased
risk of death or transplantation at 12 months included a
smaller size (as evidenced by a lower BSA), greater
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TABLE 2. Hemodynamic variables by actual shunt type
Hemodynamic variable

Total (n ¼ 387)

MBTS (n ¼ 170)

RVPAS (n ¼ 217)

P value

Aortic diastolic pressure (mm Hg)
Coronary perfusion pressure (mm Hg)
Ventricular end diastolic pressure (mm Hg)
Aortic saturation (%)
Superior vena cava saturation (%)
Qp/Qs ratio
Mean pulmonary artery pressure (mm Hg)
Pulmonary vascular resistance (Wood unit 3 m2)
General anesthesia for procedural sedation

38  8
29  8
8.3  3.3
75  6
50  8
1.0 (0.8-1.4)
15 (13-17)
2.0 (1.3-2.6)
242 (63)

35  7
27  8
8.7  3.4
75  5
50  8
1.1 (0.8-1.5)
14 (13-17)
2.0 (1.3-2.3)
95 (56)

40  7
32  8
7.9  3.2
74  6
50  8
1.0 (0.8-1.3)
15 (12-18)
2.0 (1.4-2.8)
147 (69)

<.001
<.001
.02
.09
.54
.009
.98
.25
.01

ventricular EDP, and lower SVC saturation. A greater EDP,
likely reflective of poor diastolic function or increased
pulmonary blood flow, would also result in increased pulmonary artery pressure after the stage II procedure. A lower
SVC saturation might have represented poor cardiac output
or lower arterial oxygen saturation. It was not surprising
that both parameters were associated with worse outcomes
at 12 months. With respect to the comparison of hemodynamic parameters by shunt type, our analysis was consistent
with previous reports regarding the retrograde aortic flow
pattern,11 lower aortic diastolic pressure, and lower coronary perfusion pressure in the MBTS subjects.12 Although
clear data are lacking, the latter finding might result in
chronic injury to the ventricular myocardium in the
MBTS subjects, which could explain the finding in the
SVR trial of lower transplant-free survival at 12 months
in the MBTS subjects. In contrast, RVPAS subjects will
require a ventriculotomy, which could negatively affect
late ventricular function and result in the development of
ventricular arrhythmias. This could, in turn, offset the early
advantages of greater coronary perfusion pressure.13 However, this potential disadvantage of a right ventriculotomy
for RVPAS subjects has remained controversial. Tanoue
and colleagues14 found that, after the stage II procedure,
the RVPAS subjects had worse right ventricular systolic
function than did the MBTS subjects. Owing to concerns
regarding late ventricular dysfunction, Ballweg and colleagues3 analyzed 124 infants who had undergone a stage

II procedure for single ventricle physiology and reported
no difference in 3-year survival, although the RVPAS subjects had a greater incidence of ventricular dysfunction by
echocardiography at the stage II procedure. Graham and
colleagues13 demonstrated no difference in hospital survival when comparing shunt types for 76 infants with single
ventricle physiology but greater interstage mortality for
MBTS subjects (22% vs 3%, P ¼ .05). These results
have been supported by Mahle and colleagues,15 who reported operative and 1-year survival of 81% for RVPAS
subjects, with no difference in the Qp/Qs ratio or survival
between shunt types, suggesting that equivalent pulmonary
blood flow will result in equivalent survival.
Angiographic Findings
The analysis of our data have demonstrated that overall
pulmonary artery growth was less in the RVPAS group
and that no angiographic measurement was associated
with the 12-month transplant-free survival. During the
interstage period, pulmonary artery growth is dependent
on the blood flow entering the branch pulmonary arteries
across the surgical shunt. The potential explanations for
the differences in branch pulmonary artery growth patterns
include anatomic abnormalities with the shunt or branch
pulmonary arteries16 and hemodynamic factors, such as
shunt diameter12 and pulsatile vs nonpulsatile shunt blood
flow.11 In contrast to our findings of inferior pulmonary artery growth in the RVPAS cohort, Januszewska and

TABLE 3. Angiographic pulmonary artery and shunt abnormalities by shunt type
Angiographic abnormality

Total (n ¼ 348)

MBTS (n ¼ 152)

RVPAS (n ¼ 196)

P value

Mid main RPA stenosis
Severe RPA stenosis, any location
Mid main LPA stenosis
Severe LPA stenosis, any location
All shunt stenosis
Proximal shunt stenosis

110 (32)
33 (9)
79 (23)
19 (5)
75 (22)
33 (10)

38 (25)
9 (6)
30 (20)
1 (1)
21 (14)
6 (4)

72 (37)
24 (12)
49 (25)
18 (9)
54 (28)
27 (14)

.02
.18
.30
.003
.004
.008

Data presented as n (%). P values comparing MBTS and RVPAS group were determined using the Fisher exact test. MBTS, Modified Blalock-Taussig shunt; RVPAS, right
ventricle-to-pulmonary artery shunt; RPA, right pulmonary artery; LPA, left pulmonary artery.
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Data presented as mean  standard deviation, median (interquartile range), or n (%). P values comparing MBTS and RVPAS groups were determined using the Student t test for
the mean values, Wilcoxon rank sum test for the median values, and Fisher exact test for frequencies. MBTS, Modified Blalock-Taussig shunt; RVPAS, right ventricle-topulmonary artery shunt; Qp, pulmonary blood flow; Qs, systemic blood flow.
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TABLE 4. Pulmonary artery measurements by shunt type
Measurement

Total (n ¼ 348)

MBTS (n ¼ 152)

RVPAS (n ¼ 196)

P value

Mid-main LPA (mm)
Mid-main LPA, indexed (mm/m2)
Mid-main RPA (mm)
Mid-main RPA, indexed (mm/m2)
Proximal right lower lobe (mm)
Proximal right lower lobe, indexed (mm/m2)
Proximal left lower lobe (mm)
Proximal left lower lobe, indexed (mm/m2)
Nakata index (mm2/m2)

4.5 (3.6-5.7)
15.1 (11.9-17.9)
4.6 (3.6-5.7)
15.0 (11.6-18.4)
5.7  1.8
18.4  5.6
5.3  1.6
17.3  5.2
147 (110-196)

4.8 (4.0-6.0)
15.8 (13.0-18.4)
5.0 (4.0-6.1)
16.5 (13.0-19.9)
6.3  2.1
20.7  6.2
5.4  1.6
17.6  5.1
164 (125-226)

4.3 (3.4-5.4)
14.2 (11.3-17.5)
4.2 (3.4-5.2)
13.9 (10.7-17.1)
5.1  1.4
16.7  4.4
5.2  1.7
17.1  5.4
134 (100-180)

.009
.003
<.001
<.001
<.001
<.001
.54
.36
<.001

Data presented as mean  standard deviation or median (interquartile range). Indexed data were indexed to the body surface area at catheterization. P values comparing MBTS
and RVPAS groups were determined using the Student t test for the mean and Wilcoxon rank sum test for the median values. MBTS, Modified Blalock-Taussig shunt; RVPAS, right
ventricle-to-pulmonary artery shunt; LPA, left pulmonary artery; RPA, right pulmonary artery.

colleagues17 reported that although the RVPAS subjects had
a significantly lower Qp/Qs ratio (0.8 vs 1.2), lower aortic
oxygen saturation (67.4% vs 75.3%), and lower SVC oxygen saturation (43.5% vs 49.7%), they had good, symmetric pulmonary artery growth before the stage II procedure.
One purported advantage of the RVPAS is that it allows pulsatile flow into the branch pulmonary arteries, which might
improve interstage pulmonary artery growth, compared
with the MBTS, which provides continuous flow.
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Shunt and Pulmonary Artery Stenosis
Stenoses of the shunt or branch pulmonary arteries can
have significant adverse effects in this patient population.
Obstruction to shunt-dependent blood flow will result in
poor branch pulmonary artery growth,18 and branch pulmonary artery hypoplasia is a risk factor at the stage II procedure.19,20 In addition, the presence of central pulmonary
artery stenoses frequently requires catheter-based interventions or surgical revision at the stage II procedure.4,16 For
the entire cohort and irrespective of shunt type, branch
pulmonary artery stenosis occurred nearly 50% of the
time in both the LPA and the RPA. This finding was
consistent with a report from Griselli and colleagues16
that 50% of infants undergoing a Norwood procedure
developed central pulmonary artery stenosis that required
surgical revision during the stage II procedure. In our angiographic analyses, the RVPAS subjects had more often had
stenosis in the shunt, more often developed moderate-tosevere branch pulmonary artery stenosis, and had a significantly smaller absolute diameter of the stenotic portion of
the RPA. Our data have demonstrated that the Nakata index
before the stage II procedure was lower than that previously
reported for both shunt types and was significantly lower for
RVPAS subjects. This is in contrast to previous singlecenter, nonrandomized studies that have reported that subjects with an RVPAS, compared with an MBTS, have larger
branch pulmonary arteries at the stage II procedure.21
By defining the specific branch pulmonary artery measurement locations (Figure 1), our analysis was potentially
1472

able to avoid using the stenotic lesion for part of the measurement. In the presence of complex stenoses, the diameter
of the proximal lower lobe pulmonary arteries might provide a more accurate assessment of the branch pulmonary
artery growth. Determination of the clinical significance
of the differences in branch pulmonary artery size among
the survivors will require longer term follow-up. The
RVPAS group had a significantly smaller mid-main LPA,
mid-main RPA, and proximal right lower lobe pulmonary
artery, and the proximal left lower lobe pulmonary artery diameters were similar. Moreover, the RVPAS subjects had a
1-year transplant-free survival advantage in the SVR trial.8
It is possible that the hemodynamic effects are more important and will ultimately outweigh the effects of smaller pulmonary arteries.
Study Limitations
Data on other factors that could affect survival, such as
aortic arch obstruction, ventricular function, and atrioventricular valve regurgitation, were limited. We consciously
did not analyze detailed surgical shunt features, such as
size, length, insertion site, beveled anastomosis, and innominate artery size. Assumptions regarding the calculation of
coronary perfusion pressure might have been erroneous in
subjects with concomitant aortic arch obstruction. The
mode of sedation was different between the 2 groups and
might have affected the hemodynamic measures. Because
of the study design, we had no hemodynamic or angiographic information for the subjects with interstage mortality. Also, because a greater number of MBTS subjects died
during Norwood hospitalization or during the interstage
period, the potential for a survivor bias was present and
might have affected the shunt type comparisons. The shunt
comparisons and associations with 12-month transplantfree survival were performed without adjustment for potential confounders owing to the limited number of deaths and
cardiac transplants. Finally, because of the limited number
of events in the transplant-free survival analyses, the statistical power to detect significant findings was limited.
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CONCLUSIONS
Our analysis of pre–stage II catheterization data for SVR
trial subjects has shown that, compared with the RVPAS
subjects, the MBTS subjects had more hemodynamic abnormalities related to shunt physiology, including lower
systemic diastolic and coronary perfusion pressures, greater
ventricular EDPs, and greater Qp/Qs ratios. In contrast, the
RVPAS subjects had more shunt or pulmonary obstruction
of a severe degree and inferior pulmonary artery growth
at pre–stage II catheterization. A lower BSA, greater ventricular EDP, and lower SVC saturation were associated
with worse 12-month transplant-free survival for the entire
cohort, and no single angiographic measurement had such
an association.
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